Prognostic Factors for Outcomes in Allogeneic Transplantation for CML in the Imatinib Era: a CIBMTR Analysis

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2011 Oct 12

PMID 21986636

Citations 34

Authors

H J Khoury

M Kukreja

J M Goldman

T Wang

J Halter

M Arora

V Gupta

D A Rizzieri

B George

A Keating

R P Gale

D I Marks

P L McCarthy

A Woolfrey

J Szer

S A Giralt

R T Maziarz

J Cortes

M M Horowitz

S J Lee

Affiliations

Soon will be listed here.

Abstract

Allogeneic hematopoietic SCT is an effective treatment in accelerated (AP) or blast phase (BP) CML. Imatinib (IM) has transient but significant activity in advanced phases of CML, which may permit early allografting for responding patients. To identify prognostic factors in allograft recipients previously treated with IM, we analyzed 449 allogeneic hematopoietic SCTs performed from 1999 to 2004 in advanced-phase CML, using the data reported to the Center for International Blood and Marrow Transplant Research. CML patients in second chronic phase (CP2, n=184), AP (n=185) and BP (n=80) received HLA-identical sibling (27%), related (3%), or matched or mismatched unrelated donor (70%), peripheral blood (47%) or BM (53%) hematopoietic SCT after myeloablative (78%) or non-myeloablative (22%) conditioning. In all, 52% in CP2, 49% in AP and 46% in BP received IM before hematopoietic SCT. Disease-free survival was 35-40% for CP2, 26-27% for AP and 8-11% for BP. Cumulative incidence of acute and chronic GVHD and TRM were not affected by the stages of CML or pre-hematopoietic SCT IM exposure. Multivariate analyses showed that conventional prognostic indicators remain the strongest determinants of transplant outcomes. In conclusion, there are no new prognostic indicators of the outcomes of allogeneic hematopoietic SCT for advanced-phase CML in the IM era.

Citing Articles

Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on Behalf of the Polish Adult Leukemia Group.

Giordano U, Piekarska A, Prejzner W, Gil L, Zaucha J, Kujawska J Biomedicines. 2025; 13(1).

PMID: 39857747 PMC: 11759780. DOI: 10.3390/biomedicines13010163.

An Overview of Myeloid Blast-Phase Chronic Myeloid Leukemia.

Pamuk G, Ehrlich L Cancers (Basel). 2024; 16(21).

PMID: 39518058 PMC: 11545322. DOI: 10.3390/cancers16213615.

The Contemporary Role of Hematopoietic Stem Cell Transplantation in the Management of Chronic Myeloid Leukemia: Is It the Same in All Settings?.

Elmakaty I, Saglio G, Al-Khabori M, Elsayed A, Elsayed B, Elmarasi M Cancers (Basel). 2024; 16(4).

PMID: 38398145 PMC: 10886670. DOI: 10.3390/cancers16040754.

The Impact of Pretransplant Use of Tyrosine Kinase Inhibitors on Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia - A Single-institution Retrospective Study.

Fujita S, Kasahara H, Kato J, Koda Y, Shiroshita K, Yamaguchi K Intern Med. 2023; 63(11):1549-1562.

PMID: 37899244 PMC: 11189713. DOI: 10.2169/internalmedicine.2479-23.

Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplantation.

Uhm J Blood Res. 2023; 58(S1):109-113.

PMID: 37105565 PMC: 10133855. DOI: 10.5045/br.2023.2023054.

References

Bornhauser M, Kroger N, Schwerdtfeger R, Schafer-Eckart K, Sayer H, Scheid C . Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study. Eur J Haematol. 2005; 76(1):9-17. DOI: 10.1111/j.0902-4441.2005.t01-1-EJH2321.x. View

Passweg J, Walker I, Sobocinski K, Klein J, Horowitz M, Giralt S . Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol. 2004; 125(5):613-20. DOI: 10.1111/j.1365-2141.2004.04955.x. View

Saussele S, Lauseker M, Gratwohl A, Beelen D, Bunjes D, Schwerdtfeger R . Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood. 2009; 115(10):1880-5. DOI: 10.1182/blood-2009-08-237115. View

Kantarjian H, OBrien S, Cortes J, Smith T, Rios M, Shan J . Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002; 8(7):2167-76. View

Perz J, Khorashad J, Marin D, Apperley J, Olavarria E . Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia. Haematologica. 2006; 91(8):1145-6. View

Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M . Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood. 2005; 106(9):2969-76. DOI: 10.1182/blood-2004-09-3544. View

Gratwohl A, Hermans J, Goldman J, Arcese W, Carreras E, Devergie A . Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998; 352(9134):1087-92. DOI: 10.1016/s0140-6736(98)03030-x. View

Zaucha J, Prejzner W, Giebel S, Gooley T, Szatkowski D, Kalwak K . Imatinib therapy prior to myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant. 2005; 36(5):417-24. DOI: 10.1038/sj.bmt.1705087. View

Weisdorf D, Spellman S, Haagenson M, Horowitz M, Lee S, Anasetti C . Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant. 2008; 14(7):748-58. PMC: 2668157. DOI: 10.1016/j.bbmt.2008.04.003. View

10.

Kantarjian H, Cortes J, OBrien S, Giles F, Albitar M, Rios M . Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002; 99(10):3547-53. DOI: 10.1182/blood.v99.10.3547. View

11.

Kantarjian H, Giles F, Wunderle L, Bhalla K, OBrien S, Wassmann B . Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006; 354(24):2542-51. DOI: 10.1056/NEJMoa055104. View

12.

Shimoni A, Kroger N, Zander A, Rowe J, Hardan I, Avigdor A . Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia. 2003; 17(2):290-7. DOI: 10.1038/sj.leu.2402808. View

13.

Druker B, Guilhot F, OBrien S, Gathmann I, Kantarjian H, Gattermann N . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355(23):2408-17. DOI: 10.1056/NEJMoa062867. View

14.

Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J . Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27(35):6041-51. PMC: 4979100. DOI: 10.1200/JCO.2009.25.0779. View

15.

Lee S, Kukreja M, Wang T, Giralt S, Szer J, Arora M . Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood. 2008; 112(8):3500-7. PMC: 2954751. DOI: 10.1182/blood-2008-02-141689. View

16.

Talpaz M, Silver R, Druker B, Goldman J, Gambacorti-Passerini C, Guilhot F . Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002; 99(6):1928-37. DOI: 10.1182/blood.v99.6.1928. View

17.

Wassmann B, Pfeifer H, Scheuring U, Klein S, Gokbuget N, Binckebanck A . Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Leukemia. 2002; 16(12):2358-65. DOI: 10.1038/sj.leu.2402770. View

18.

Sawyers C, Hochhaus A, Feldman E, Goldman J, Miller C, Ottmann O . Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002; 99(10):3530-9. DOI: 10.1182/blood.v99.10.3530. View

19.

Oehler V, Gooley T, Snyder D, Johnston L, Lin A, Cummings C . The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood. 2006; 109(4):1782-9. PMC: 1794075. DOI: 10.1182/blood-2006-06-031682. View

20.

Deininger M, Schleuning M, Greinix H, Sayer H, Fischer T, Martinez J . The effect of prior exposure to imatinib on transplant-related mortality. Haematologica. 2006; 91(4):452-9. View